← NewsAll
TrumpRx aims to make healthcare prices more transparent, says CMS administrator
Summary
CMS Administrator Dr. Mehmet Oz said the TrumpRx site currently lists 43 drugs and is intended to increase price transparency by publishing cash‑pay prices for people without insurance.
Content
The administration has introduced the TrumpRx website as a tool to publish lower cash‑pay drug prices and increase transparency in medication costs. CMS Administrator Dr. Mehmet Oz said the site currently lists 43 medications and is aimed at people without insurance, a group he estimated at about 27 million. Oz described negotiations with major drug companies and the use of "most favored nation" pricing as part of the approach, and said the site has already drawn millions of unique visitors and tens of thousands of prescriptions downloaded. Officials said they plan to expand the list of medications over time and that transparency should influence employers and other purchasers of drugs.
Key points:
- TrumpRx currently lists 43 medications and focuses initially on cash‑pay prices.
- Administrator Dr. Mehmet Oz said the site targets people without insurance, about 27 million, and is free to use.
- Oz described negotiations with major pharmaceutical companies and referenced "most favored nation" pricing.
- Officials reported millions of unique visitors to the site and tens of thousands of prescriptions downloaded.
- Oz cited examples such as GLP‑1 weight‑loss medications and fertility drugs, noting large price reductions in some categories.
- The site’s design was credited to Joe Gebbia and engineer Ed Coristine, and officials said they plan to add more medications over time.
Summary:
The administration frames TrumpRx as a transparency tool that started with 43 drugs and cash‑pay pricing for uninsured people. Officials say the site has attracted millions of visitors and that more medications will be added over time to broaden the program's reach. Timing for expansions and effects on insured patients' costs were not specified, so the next steps are undetermined at this time.
